Sangamo Biosciences (SGMO) 6.52 $SGMO Sangamo

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sangamo Biosciences (SGMO) 6.52 $SGMO

Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast
PR Newswire - Wed Jul 27, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the company will release its second quarter 2016 financial results after the market closes on Wednesday, August 3, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of Hemophilia A
PR Newswire - Tue Jul 26, 10:45AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the presentation of preclinical data that supports the clinical development of its new proprietary gene therapy for the treatment of hemophilia A. This new therapeutic comprises an adeno-associated virus (AAV) cDNA human Factor 8 (hF8) construct driven by Sangamo's proprietary synthetic liver specific promoter, which in preclinical studies is at least three times more potent than existing AAV-based cDNA constructs currently under evaluation for the treatment of hemophilia A.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces Participation At Upcoming Scientific Conferences in July
PR Newswire - Tue Jul 12, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that members of the Company's research and development team will participate in the following scientific conferences in July.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
PR Newswire - Mon Jun 20, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) for SB-913, a zinc finger nuclease (ZFN)-mediated approach designed as a single treatment with the potential to provide a long-lasting therapy for Mucopolysaccharidosis Type II (MPS II, Hunter syndrome). The IND is now active and enables Sangamo to initiate a Phase 1/2 clinical trial (SB-913-1602) to assess the safety, tolerability and potential efficacy of SB-913 in adults with MPS II.
SGMO: 6.52 (+0.19)

Global Thalassemia Market Report: 2016 Edition - Gene Therapy for Curing Thalassemia/ Advances in Iron Chelation Therapy / Fetal Hemoglobin Inducers - Research and Markets
BusinessWire - Fri Jun 10, 4:19AM CDT
Research and Markets has announced the addition of the "Global Thalassemia Market Report: 2016 Edition" report to their offering.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces Presentation at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's founder and former president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:30 am ET on Wednesday, June 8, 2016, at the Jefferies 2016 Healthcare Conference. Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's newly appointed president and chief executive officer will also be attending the conference, which is being held in New York from June 7-10, 2016.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor
PR Newswire - Wed Jun 01, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander 'Sandy' Macrae, M.B., Ch.B, Ph.D., MRCP, as president and chief executive officer to succeed current president and CEO, Edward Lanphier. Mr. Lanphier is retiring from the day-to-day leadership of Sangamo. He will continue as a member of the board of directors and, as previously disclosed, will assume the chairmanship of the board immediately following the 2016 annual meeting of stockholders which will be held on June 14, 2016. Mr. William Ringo, Sangamo's current chairman since 2010, will remain on the board as chairman of the Nominating and Governance Committee and member of the Compensation Committee. Dr. Macrae has assumed the CEO role effective today.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces Participation At Upcoming Investor Conferences
PR Newswire - Tue May 10, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will participate in the following upcoming conferences.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 02, 3:05PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its first quarter 2016 financial results and accomplishments.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces Presentation At The Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Thu Apr 28, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:20 am ET on Thursday, May 5, 2016, at the Deutsche Bank 41st Annual Health Care Conference. The conference is being held in Boston from May 4-5, 2016.
SGMO: 6.52 (+0.19), DB: 13.17 (-0.27)

Sangamo BioSciences Announces First Quarter 2016 Conference Call and Webcast
PR Newswire - Mon Apr 25, 3:03PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its first quarter 2016 financial results after the market closes on Monday, May 2, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces Presentations On ZFP Therapeutic® Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy
PR Newswire - Mon Apr 18, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from several ZFP Therapeutic programs will be presented at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) to be held in Washington, D.C. from May 4-7, 2016.
SGMO: 6.52 (+0.19)

Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 11.12 (+0.26), CMRX: 4.13 (+0.14), GERN: 2.71 (+0.03), CYTX: 2.15 (-0.02), CLDX: 4.67 (+0.05), SGMO: 6.52 (+0.19), PTCT: 6.21 (+0.24), ATHX: 2.17 (-0.05), MNKD: 1.00 (+0.01)

Sangamo BioSciences Announces Participation In The 4th Annual Cell & Gene Therapy Investor Day Meeting In New York
PR Newswire - Tue Mar 15, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice president, corporate communications, will present an overview of the Company's ZFP Therapeutic® programs at 11:15am ET on Tuesday, March 22, 2016, at the 4th Annual Cell & Gene Therapy Investor Day. The meeting will be held in New York City.
SGMO: 6.52 (+0.19)

Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 11.12 (+0.26), VCEL: 2.29 (+0.03), SGMO: 6.52 (+0.19), ZYNE: 9.42 (+0.58)

Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results
PR Newswire - Tue Feb 09, 3:03PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.
SGMO: 6.52 (+0.19)

Shares of SGMO Down 24.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 05, 6:42PM CST
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on January 8th, 2016 at $7.70. In approximately 4 weeks, Sangamo Biosciences has returned 24.89% as of today's recent price of $5.78.
SGMO: 6.52 (+0.19)

Sangamo BioSciences Announces Presentation At The Leerink Partners 5th Annual Global Healthcare Conference
PR Newswire - Thu Feb 04, 3:03PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:40 pm ET on Thursday, February 11, 2016, at the Leerink Partners 5th Annual Global Healthcare Conference. The conference is being held in New York.
SGMO: 6.52 (+0.19)

Sickle Cell Disease Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44gnx8/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Sickle Cell Disease Overview - Therapeutics Development - Pipeline Products for Sickle Cell Disease - Overview - Pipeline Products for Sickle Cell Disease - Comparative Analysis - Sickle Cell Disease - Therapeutics under Development by Companies - Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes - Sickle Cell Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Sickle Cell Disease - Products under Development by Companies - Sickle Cell Disease - Products under Investigation by Universities/Institutes - Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Complexa, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - La Jolla Pharmaceutical Company - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sancilio & Company, Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/44...ickle_cell
JNJ: 125.16 (-0.07), GBT: 17.93 (+0.05), ISIS: 57.56 (-0.28), GILD: 80.19 (+0.72), PFE: 37.30 (+0.41), SGMO: 6.52 (+0.19), BMY: 75.78 (+0.97), NVS: 83.21 (-0.05), XLRN: 34.55 (+0.63)

Sangamo BioSciences Announces Fourth Quarter And Full Year 2015 Conference Call And Webcast
PR Newswire - Tue Feb 02, 3:03PM CST
Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its fourth quarter and full year 2015 financial results after the market closes on Tuesday, February 9, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 6.52 (+0.19)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 173

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 123

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 203

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaker’s TruSend™: A Game Changer in Email Marketing

Updated Category News Views 142

Breaker’s TruSend™: A Game Changer in Email Marketing In the fast-evolving world of marketing, email continues to hold its ground as a vital communication tool. Breaker has recognized the challenges marketers face with fragmented tech stacks and has introduced TruSend™, a robust email distribution platform. This innovation streamlines the email marketing process,...

Continue Reading
DigiKey and Qorvo Collaborate to Enhance Global Distribution

Updated Category News Views 151

DigiKey and Qorvo Forge Strategic Distribution Partnership DigiKey, a prominent global distributor known for its vast selection of technical components and automation products, has entered into a vital distribution agreement with Qorvo®, a leader in connectivity and power solutions. This collaboration aims to boost the availability and delivery speed of Qorvo's...

Continue Reading
Lloyds Bank's Financial Insights for 2025: A Comprehensive Review

Updated Category News Views 345

Overview of Lloyds Bank plc's 2025 Half-Year Results Lloyds Bank plc, a prominent player in the financial services sector, has released its half-year results for 2025, demonstrating resilience and strategic agility. As a member of the Lloyds Banking Group, it continues to show its commitment to delivering value to its stakeholders and customers. Key Financial Highlights...

Continue Reading
Advansor's Latest CO2 Enclosure Solutions Revolutionize Climate Control

Updated Category News Views 97

Advansor Introduces a New Range of CO2 Enclosures Advansor, a leading name in climate solutions, has recently unveiled an innovative line of CO2 enclosures tailored for supermarkets, cold storage facilities, and industrial applications. These enclosures are designed to simplify on-site installations and offer flexible options for outdoor placement. This groundbreaking...

Continue Reading
LG Innotek's Revolutionary Automotive AP Module Enhances Mobility

Updated Category News Views 220

LG Innotek's Innovative Entry into Automotive Semiconductor Market LG Innotek has taken a significant step into the automotive semiconductor component market with the launch of its Automotive Application Processor Module (AP Module). This move comes in response to a growing demand for sophisticated automotive technologies, particularly in the realm of Advanced Driver...

Continue Reading